publication venue for
- Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. 2024
- Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. 2022
- Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance. 2020
- Cancer and COVID-19 - potentially deleterious effects of delaying radiotherapy.. 17. 2020
- Precision oncology in non-small-cell lung cancer: opportunities and challenges.. 15. 2018
- Small-cell lung cancer in 2016: Shining light on novel targets and therapies.. 14. 2016
- Radiotherapy: has the role of WBRT in primary CNS lymphoma been settled?. 8. 2011
- Decade in review-funding in cancer research: National Cancer Institute awards-a work in progress.. 11. 2014
- Decade in review--genomics: a decade of discovery in cancer genomics.. 11. 2014
- Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era.. 11. 2013
- Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.. 10. 2013
- Urological cancer: Time for another rethink on prostate cancer screening.. 9. 2011
- 200 mg/m(2) melphalan--the gold standard for multiple myeloma.. 7. 2010
- Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer.. 7. 2010
- The KRYSTAL-1 study of adagrasib - a new trial for KRASG12C-mutated non-small-cell lung cancer. 2022
- Lung cancer: First-line immunotherapy in lung cancer - taking the first step. 2016
- Sarcoma: primary retroperitoneal sarcoma-predicting survival. 2013
- Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. 2019
- Correction regarding data on blinatumomab-associated seizures. 2016
- Imaging biomarker roadmap for cancer studies. 2016
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. 2013
- ROS1-dependent cancers - biology, diagnostics and therapeutics. 2020
- MET-dependent solid tumours - molecular diagnosis and targeted therapy. 2020
- NTRK fusion-positive cancers and TRK inhibitor therapy. 2018
- Treatment resistance in urothelial carcinoma: an evolutionary perspective. 2018
- The emerging clinical relevance of genomics in cancer medicine. 2018
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. 2017
- Drug development for noncastrate prostate cancer in a changed therapeutic landscape. 2017
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. 2017
- Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. 2016
- Non-invasive metabolic imaging of brain tumours in the era of precision medicine. 2016
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. 2016
- Clinical impact of tumour biology in the management of gastroesophageal cancer. 2016
- Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. 2015
- Minimal residual disease in multiple myeloma: bringing the bench to the bedside. 2015
- High-risk prostate cancer-classification and therapy. 2014
- Validation and clinical utility of prostate cancer biomarkers. 2013
- Prostate cancer in 2011: Hitting old targets better and identifying new targets. 2012
- Noninvasive cell-tracking methods. 2011
- Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. 2010
- BRAF - a tumour-agnostic drug target with lineage-specific dependencies. 2024
- Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. 2024
- Emerging evidence for adapting radiotherapy to immunotherapy. 2023
- Improving outcomes in patients with oesophageal cancer. 2023
- Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. 2022
- Clinical implications of T cell exhaustion for cancer immunotherapy. 2022
- Is early-onset cancer an emerging global epidemic? Current evidence and future implications. 2022
- Radiotheranostics in oncology: current challenges and emerging opportunities. 2022
- Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. 2021
- Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. 2021
- Immunogenicity of CAR T cells in cancer therapy. 2021
- Unlocking the potential of antibody-drug conjugates for cancer therapy. 2021
- Lineage plasticity in cancer: a shared pathway of therapeutic resistance. 2020
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy. 2019
- Towards individualized therapy for metastatic renal cell carcinoma. 2019
- Challenges to curing primary brain tumours. 2019
- Emerging epigenetic-modulating therapies in lymphoma. 2019
- Accelerating anticancer drug development - opportunities and trade-offs. 2018
- Unravelling the biology of SCLC: implications for therapy. 2017
- The high price of anticancer drugs: origins, implications, barriers, solutions. 2017
- Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. 2016
- Genomic complexity of multiple myeloma and its clinical implications. 2016
- Counselling framework for moderate-penetrance cancer-susceptibility mutations. 2016
- Population-based screening for cancer: hope and hype. 2016
- Molecular therapy for acute myeloid leukaemia. 2015
- Cancer-treatment-induced neurotoxicity--focus on newer treatments. 2015
- Refining the treatment of NSCLC according to histological and molecular subtypes. 2015
- Current management of lesions associated with an increased risk of breast cancer. 2015
- Precision therapy for lymphoma--current state and future directions. 2014
- Can we deliver randomized trials of focal therapy in prostate cancer? 2014
- Lung cancer in 2013: Refining standard practice and admitting uncertainty. 2014
- Molecular targets on the horizon for kidney and urothelial cancer. 2013
- The future of epigenetic therapy in solid tumours--lessons from the past. 2013
- Reducing the toxicity of cancer therapy: recognizing needs, taking action. 2012
- The role of local therapy in the management of lung and liver oligometastases. 2011
- Clinical implications of cancer self-seeding. 2011
- Metastasis-suppressor genes in clinical practice: lost in translation? 2011
- Molecular mechanisms of metastasis in breast cancer--clinical applications. 2010
- Stereotactic body radiation therapy: a novel treatment modality. 2009
- Molecular targets for treatment of inflammatory breast cancer. 2009
- Next generation oncology drug development: opportunities and challenges. 2009